Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma

Modern Pathology

Volumn 27, Issue 3, 2014, Pages 402-411

  Pham Ledard, Anne ^a,b   Prochazkova Carlotti, Martina ^a   Andrique, Laetitia ^a   Cappellen, David ^a,b   Vergier, Béatrice ^b   Martinez, Fabian ^b   Grange, Florent ^c   Petrella, Tony ^d   Beylot Barry, Marie ^a,b   Merlio, Jean Philippe ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

BCL2; BCL6; Diffuse large B cell lymphoma; MYC; MYD88; NF B; Primary cutaneous large B cell lymphoma leg type

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME 6Q; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LEG; MALE; MIDDLE AGED; MOLECULAR PROBE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LYMPHOMA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LEG; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84896702621     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.156     Document Type: Article

References (50)

1. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol 1996;132: 1304-1308.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
3. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007;143: 1144-1150.
4. Swerdlow SH, Campo E, Lee Harris N, et al. (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon; 2008; p 242.
5. Hoefnagel JJ, Mulder MMS, Dreef E, et al. Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Mod Pathol 2006;19: 1270-1276.
6. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007;25: 1581-1587.
7. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006;24: 1376-1382.
8. Senff NJ, Zoutman WH, Vermeer MH, et al. Finemapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2009;129: 1149-1155.
9. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403: 503-511.
10. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 1937-1947.
11. Hoefnagel JJ, Dijkman R, Basso K,J, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005;105: 3671-3678.
12. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282.
13. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29: 200-207.
14. Pham-Ledard A, Prochazkova-Carlotti M, Vergier B, et al. IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2010; 130: 1470-1472.
15. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma. Nature 2010;463: 88-92.
16. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470: 115-119.
17. Shaffer AL, Emre NCT, Romesser PB, et al. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 2009;15: 2954-2961.
18. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459: 717-721.
19. Yang Y, Shaffer AL, Emre NCT, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012;21: 723-737.
20. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362: 1417-1429.
21. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010;18: 568-579.
22. Pham-Ledard A, Cappellen D, Martinez F, et al. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2012;132: 2118-2120.
23. Grange F, Maubec E, Bagot M, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol 2009;145: 329-330.
24. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235-242.
25. Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 2013;98: 255-263.
26. Barrans SL, O'Connor SJM, Evans PAS, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002;117: 322-332.
27. Copie-Bergman C, Gaulard P, Leroy K, et al. Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009;27: 5573-5579.
28. Shustik J, Han G, Farinha P, et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 2010;95: 96-101.
29. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28: 3360-3365.
30. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114: 3533-3537.
31. Jardin F, Jais J-P, Molina T-J, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 2010;116: 1092-1104.
32. Belaud-Rotureau M-A, Marietta V, Vergier B, et al. Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. Virchows Arch 2008;452: 607-620.
33. Hallermann C, Kaune KM, Siebert R, et al. Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas. J Invest Dermatol 2004;122: 1495-1502.
34. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003;149: 1183-1191.
35. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE 2012;7:e33813.
36. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002;99: 409-426.
37. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203: 311-317.
38. Tam W, Gomez M, Chadburn A, et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006;107: 4090-4100.
39. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002;17: 51-62.
40. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354: 2431-2442.
41. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114: 2273-2279.
42. Snuderl M, Kolman OK, Chen Y-B, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34: 327-340.
43. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30: 3460-3467.
44. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121: 2253-2263.
45. Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol 2006;24: 296-305.
46. Wiesner T, Obenauf AC, Geigl JB, et al. 9p21 deletion in primary cutaneous large B-cell lymphoma, leg type, may escape detection by standard FISH assays. J Invest Dermatol 2009;129: 238-240.
47. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194: 1861-1874.
48. Rui L, Schmitz R, Ceribelli M, et al. Malignant pirates of the immune system. Nat Immunol 2011;12: 933-940.
49. Hernandez-Ilizaliturri FJ, Deeb G, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-celllike thanin germinal center B-cell-like phenotype. Cancer 2011;117: 5058-5066.
50. Bhagavathi S, Blenc AM, Amin M, et al. Primary cutaneous large B-cell lymphoma shows activation of nuclear factor kappa B and low incidence of Epstein- Barr virus. Am J Dermatopathol 2010;32: 439-441.